The latest price target for Generation Bio (NASDAQ:GBIO) was reported by Wedbush on December 16, 2025. The analyst firm set a price target for $5.50 expecting GBIO to rise to within 12 months (a possible 1.10% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Generation Bio (NASDAQ:GBIO) was provided by Wedbush, and Generation Bio upgraded their outperform rating.

The last upgrade for Generation Bio Co happened on December 16, 2025 when Wedbush raised their price target to $5.5. Wedbush previously had a neutral for Generation Bio Co.

The last downgrade for Generation Bio Co happened on December 16, 2025 when Jefferies changed their price target from $11 to $5 for Generation Bio Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Generation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Generation Bio was filed on December 16, 2025 so you should expect the next rating to be made available sometime around December 16, 2026.

While ratings are subjective and will change, the latest Generation Bio (GBIO) rating was a upgraded with a price target of $7.00 to $5.50. The current price Generation Bio (GBIO) is trading at is $5.44, which is out of the analyst’s predicted range.